LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy

Claudio Scuoppo; Shan Zha

doi:10.1016/j.ccell.2019.08.011

LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy

Cancer Cell. 2019 Sep 16;36(3):211-212. doi: 10.1016/j.ccell.2019.08.011.

Authors

Claudio Scuoppo¹, Shan Zha²

Affiliations

¹ Institute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Vagelos College for Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
² Institute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Pediatrics, Vagelos College for Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Vagelos College for Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Immunology and Microbiology, Vagelos College for Physicians and Surgeons, Columbia University, New York, NY 10032, USA. Electronic address: sz2296@cumc.columbia.edu.

PMID: 31526755
DOI: 10.1016/j.ccell.2019.08.011

Abstract

In this issue of Cancer Cell, Parvin and colleagues identify the expression of LMO2 as a biomarker for DNA repair defects in lymphomas. Using isogenic cell lines and xenografts, the authors show that expression of LMO2 predicts sensitivity to PARP inhibition, especially in combination with genotoxic therapy.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adaptor Proteins, Signal Transducing
DNA Damage
LIM Domain Proteins*
Poly(ADP-ribose) Polymerase Inhibitors*
Proto-Oncogene Proteins / genetics
Synthetic Lethal Mutations

Substances

Adaptor Proteins, Signal Transducing
LIM Domain Proteins
Poly(ADP-ribose) Polymerase Inhibitors
Proto-Oncogene Proteins